Jurisdiction--personal-_general_-specific
The trial court erred by denying the motion of defendant Japanese corporation to dismiss
based on lack of personal jurisdiction in a class action conspiracy case involving the alleged
fraudulent marketing, pricing, and sales scheme of a cancer treatment drug, because there was no
a sufficient basis for finding specific or general jurisdiction including that: (1) there was no basis
for specific jurisdiction when plaintiffs failed to provide specific facts showing that defendant
agreed to perform unlawful conduct even assuming a conspiracy theory of jurisdiction; and (2)
there was no basis for general jurisdiction when defendant has not been authorized to do business
in North Carolina and has not maintained any offices here, defendant has not manufactured, sold,
or shipped any goods in North Carolina, defendant does not own real property, has no telephone
number, and does not have a mailing address, and defendant's peripheral contacts do not
establish general jurisdiction under the totality of circumstances.
Marvin K. Blount, Jr., and Marvin K. Blount, III; and Kline &
Specter, P.C., by Donald E. Haviland, Jr., Terri Anne
Benedetto, and Louis C. Ricciardi for plaintiff appellees.
Ellis & Winters LLP, by Richard E. Ellis and Matthew W.
Sawchak, for Takeda Chemical Industries, Ltd., defendant
appellant.
McCULLOUGH, Judge.
This case arises out of an order denying defendant Takeda's
motion to dismiss for lack of personal jurisdiction entered 17
October 2002. The pertinent facts are as follows: Plaintiffs are
three North Carolina residents who purchased Lupron as part of
their treatment for prostate cancer. Defendant Takeda ChemicalIndustries, Inc. (Takeda) is a Japanese corporation headquartered
in Osaka, Japan. Plaintiffs allege that Takeda, TAP Pharmaceutical
Products, Inc. (TAP), Abbott Laboratories, and other defendants
violated various laws in connection with the marketing and pricing
of Lupron in the United States. Plaintiffs allege that defendants
were involved in a conspiracy consisting of a fraudulent marketing,
pricing, and sales scheme to defraud Lupron patients.
Takeda manufactures Lupron in Japan, but it does not design,
manufacture, package, sell, ship, or distribute Lupron in North
Carolina. Under a license granted by Takeda, Lupron is marketed by
a separate corporation located in Illinois, and sold in the United
States by TAP's subsidiary, TAP Pharmaceuticals, Inc. Takeda
indirectly owns 50% of TAP's stock. Abbott owns the other 50%.
TAP maintains its own headquarters, has its own bank account, files
its own taxes, holds regular Board of Directors meetings, and hires
and fires its own personnel. TAP also runs its daily activities
without instruction from Takeda.
From 1992 through December 2001, Takeda was not licensed or
registered to do business in North Carolina. It did not own or
lease land or maintain an address or telephone number in the state.
Takeda did not manufacture any products, sell any goods, or earn
any income from business in North Carolina. It did not even have
a registered agent for service of process in North Carolina. Prior
to January 2001, Takeda did have a subsidiary in North Carolina
known as Takeda Vitamin and Food U.S.A., Inc. (TVFU). Although
TVFU manufactured bulk vitamins, it had no involvement with Lupron.
Takeda did not have employees permanently assigned to work inthe United States, but it did second employees to American
subsidiaries from time to time. Secondment is a customary
practice among Japanese corporations with foreign subsidiaries.
Through this practice, an employee of the parent works for a period
of time as an employee of the subsidiary. The United States
subsidiary supervises the seconded employee and controls the manner
in which the employee fulfills his or her responsibilities to the
subsidiary. Takeda also maintained one bank account in Wilmington,
North Carolina, for the purpose of settling accounts related to
seconded employees. This account was closed by September of 1998.
Plaintiffs filed this class action suit on 31 December 2001,
alleging a number of claims based on the sale and marketing of
Lupron. On 17 October 2002, the trial court denied Takeda's motion
to dismiss for lack of personal jurisdiction. Defendant appeals.
On appeal, defendant argues that the trial court erred because
there was no basis for general or specific jurisdiction. We agree
and reverse the decision of the trial court.
When jurisdiction is challenged, plaintiff has the burden of
proving that jurisdiction exists. Cherry Bekaert & Holland v.
Brown, 99 N.C. App. 626, 629-30, 394 S.E.2d 651, 654 (1990). In
this case, the trial court made no findings of fact, and neither
party made such a request. Where no findings are made, proper
findings are presumed, and our role on appeal is to review the
record for competent evidence to support these presumed findings.
Bruggeman v. Meditrust Acquisition Co., 138 N.C. App. 612, 615, 532
S.E.2d 215, 217-18, disc. review denied, appeal dismissed, 353 N.C.261, 546 S.E.2d 90 (2000). This Court has articulated the standard
for determining personal jurisdiction:
The determination of personal jurisdic-
tion is a two-part inquiry. The trial court
first must examine whether the exercise of
jurisdiction over the defendant falls within
North Carolina's long-arm statute, N.C. Gen.
Stat. § 1-75.4, and then must determine
whether the defendant has sufficient minimum
contacts with North Carolina such that the
exercise of jurisdiction is consistent with
the due process clause of the Fourteenth
Amendment to the United States Constitution.
Better Business Forms, Inc. v. Davis, 120 N.C. App. 498, 500, 462
S.E.2d 832, 833 (1995). Takeda does not argue that it is beyond
the reach of North Carolina's long-arm statute. Therefore, we must
consider the remaining issue of due process.
To comply with due process, there must be minimum contacts
between the nonresident defendant and the forum so that allowing
the suit does not offend traditional notions of fair play and
substantial justice. Tom Toggs, Inc., v. Ben Elias Industries
Corp., 318 N.C. 361, 365, 348 S.E.2d 782, 786 (1986) (citing
International Shoe Co. v. Washington, 326 U.S. 310, 316, 90 L. Ed.
95, 102 (1945)). [T]here must be some act by which the defendant
purposefully avails himself of the privilege of conducting
activities within the forum state, thus invoking the benefits and
protections of its laws; the unilateral activity within the forum
state of others who claim some relationship with a non-resident
defendant will not suffice. Id.
There are two kinds of personal jurisdiction: general and
specific. A court may exercise specific jurisdiction only [w]here
the controversy arises out of the defendant's contacts with theforum state. Id. at 366, 348 S.E.2d at 786. The test for general
jurisdiction is more stringent. Id. A court may exercise general
jurisdiction where the cause of action is unrelated to defendant's
activities with the forum state if there are continuous and
systematic contacts between the defendant and the forum state.
Bruggeman, 138 N.C. App. at 617, 532 S.E.2d at 219. With these
principles in mind, we consider whether there was specific or
general jurisdiction in this case.
*** Converted from WordPerfect ***